News

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...
Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy. Eli Lilly ...
Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...
Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body ...
Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...
Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve more lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.
Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...
Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments ...
Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...
Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.
A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...